May 9, 2022
Aldose Reductase Inhibitor AT-007 Prevents Mitochondrial Dysfunction and Neurodegeneration in Sorbitol Dehydrogenase Deficiency-Induced Neuropathy
Presented by Yi Zhu, MD, PhD, Assistant Scientist, University of Miami; Amanda Lobato, PhD Candidate, University of Miami; Adriana Rebelo, PhD, Scientist, University of Miami; Tijana Canic, Research Laboratory Technician, University of Miami; Sheyum Syed, PhD, MS, Associate Professor, University of Miami; Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics; Stephan Züchner, MD, PhD, Professor and Chair, Department of Human Genetics, University of Miami; Grace Zhai, PhD, Professor of Molecular and Cellular Pharmacology
University of Miami 2022 Annual Meeting of the Peripheral Nerve Society 

AT-007 Significantly Lowers Blood Sorbitol Levels in Patients with Hereditary Neuropathy Resulting from Sorbitol Dehydrogenase (SORD) Deficiency
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Jahannaz Dastgir, DO, Director of Clinical Research at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
2022 Annual Meeting of the Peripheral Nerve Society

Circulating Sorbitol Levels and Severity of Disease in Patients with Sorbitol Dehydrogenase (SORD) Deficiency
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
2022 Annual Meeting of the Peripheral Nerve Society

Galactitol – But Not Gal-1p – Level is a Predictor of Disease Severity in Children with Classic Galactosemia on Galactose-Restricted Diet
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Evan Bailey, MD, Executive Medical Director at Applied Therapeutics; Francesca Lawson, MD, FAHA, Vice President Clinical Regulatory Strategy at Applied Therapeutics; Stella Wang, MPH, Head Medical Projects & Data Analytics at Applied Therapeutics; Laura Saltonstall, MD, MBA, Vice President Medical Affairs, Head of Medical Strategy, Operations at Applied Therapeutics; Amanda Krumnow, PharmD, MBA, Vice President Medical Affairs at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
43rd Annual Meeting of the Society for Inherited Metabolic Disorders

Baseline Disease Characteristics of 47 Pediatric Classic Galactosemia Patients in the ACTION-Galactosemia KIDS AT-007 Interventional Study Demonstrate the Multi-System Burden of Disease
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Ayesha Ahmad, MBBS, Division of Pediatric Genetics, Metabolism and Genomic Medicine, University of Michigan; Han C. Phan, MD, Director of Clinical Research, Rare Disease Research LLC, Atlanta, GA; Janet Thomas, MD, Director, Inherited Metabolic Disease Clinic, University of Colorado School of Medicine and the Children’s Hospital Colorado; Francesca Lawson, MD, FAHA, Vice President Clinical Regulatory Strategy; Evan Bailey, MD, Executive Medical Director at Applied Therapeutics; Laura Saltonstall, MD, MBA, Vice President Medical Affairs, Head of Medical Strategy, Operations at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
43rd Annual Meeting of the Society for Inherited Metabolic Disorders